Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- LaNova Australia Pty Limited
- Target Recruit Count
- 20
- Registration Number
- NCT05188664
- Locations
- 🇦🇺
The Alfred, Melbourne, Australia
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 141
- Registration Number
- NCT05173142
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT05167071
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Registration Number
- NCT05165849
Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05162898
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 57
- Registration Number
- NCT05162196
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 40
- Registration Number
- NCT05147844
- Locations
- 🇨🇳
Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China
🇨🇳the second affiliated hospital of Army medical university, Chongqing, Chongqing, China
PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 25
- Registration Number
- NCT05060471
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT05056337
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Target Recruit Count
- 129
- Registration Number
- NCT05031494
- Locations
- 🇺🇸
Ichan School of Medicine at Mount Sinai, New York, New York, United States
🇦🇺Epworth Medical Centre, Richmond, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.